Evaluation of Plasma miR-17-5p, miR-24-3p and miRNA-223-3p Profile of Hepatitis C Virus-Infected Patients after Treatment with Direct-Acting Antivirals
-
Published:2023-07-26
Issue:8
Volume:13
Page:1188
-
ISSN:2075-4426
-
Container-title:Journal of Personalized Medicine
-
language:en
-
Short-container-title:JPM
Author:
Öksüz Zehra1ORCID, Gragnani Laura23ORCID, Lorini Serena2ORCID, Temel Gülhan Örekici4, Serin Mehmet Sami1, Zignego Anna Linda2
Affiliation:
1. Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Mersin University, 33160 Mersin, Turkey 2. MASVE Interdepartmental Hepatology Center, Department of Experimental and Clinical Medicine, University of Florence, Center for Research and Innovation CRIA-MASVE, AOU Careggi, 50134 Firenze, Italy 3. Department of Translational Research & New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy 4. Department of Biostatistics, Faculty of Medicine, Mersin University, 33343 Mersin, Turkey
Abstract
The expression of miR-223-3p, miR-17-5p, and miR-24-3p was evaluated in hepatitis C virus (HCV) patient serum samples, collected before DAA treatment and after a sustained virological response (SVR). Fifty HCV patients were stratified based on their liver damage stages into three different subgroups (21 with chronic hepatitis—CH, 15 with cirrhosis, and 14 with hepatocellular carcinoma—HCC). Considering the entire HCV population, the miRNA expression levels were significantly downregulated after the SVR compared to pre-treatment ones (p < 0.05). Stratifying the patients based on liver damage, the post-SVR values of the three miRNAs were significantly downregulated compared to the pre-treatment levels for both cirrhosis and HCC patients. No significant differences emerged from the analysis of the CH group. To our knowledge, this is the first study to detail the behavior of miR-223-3p, miR-17-5p, and miR-24-3p levels in patients with HCV-related CH, cirrhosis, and HCC after DAA therapy. Our findings show that HCV-infected patients have different miRNA profiles before and after treatment with DAAs, strongly suggesting that miRNAs may be involved in the pathogenesis of HCV-related damage. In this respect, the correlation observed among the three studied miRNAs could imply that they share common pathways by which they contribute the progression of HCV-induced chronic liver damage.
Funder
Federation of European Microbiological Societies Ricerca Finalizzata 2016
Subject
Medicine (miscellaneous)
Reference44 articles.
1. European Association for the Study of the Liver (2020). EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol., 73, 1170–1218. 2. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: A meta-analysis of observational studies;Morgan;Ann. Intern. Med.,2013 3. Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R.M., Barregard, L., Bhutta, Z.A., Brenner, H., Dicker, D.J., Chimed-Orchir, O., and Dandona, R. (2017). Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study. JAMA Oncol., 3, 5245–5248. 4. The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection;Garrison;Drug Metab. Dispos.,2017 5. Direct antiviral agents (DAAs)—A new age in the treatment of hepatitis C virus infection;Spengler;Pharmacol. Ther.,2018
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|